Compare UEIC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | ICCC |
|---|---|---|
| Founded | 1986 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 55.5M |
| IPO Year | 1995 | 1995 |
| Metric | UEIC | ICCC |
|---|---|---|
| Price | $3.76 | $6.40 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.25 | N/A |
| AVG Volume (30 Days) | ★ 48.6K | 15.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.79 | 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $394,879,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.05 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $2.69 | $4.32 |
| 52 Week High | $7.90 | $7.60 |
| Indicator | UEIC | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 50.06 |
| Support Level | $3.68 | $5.72 |
| Resistance Level | $3.79 | $6.91 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 5.08 | 34.48 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.